Literature DB >> 11560874

Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures.

C Shu1, H Shen, U Hopfer, D E Smith.   

Abstract

The objective of this study was to delineate the transepithelial transport mechanisms of fosinopril in cultured cell lines expressing the intestinal and renal peptide transporters. Lineweaver-Burk, Dixon, and dose-response analyses revealed that GlySar uptake was competitively inhibited by fosinopril in both Caco-2 (K(i), 35.5 microM) and SKPT cells (K(i), 29.6 microM). Intracellular accumulations of fosinopril were 3 to 4 times higher from apical versus basolateral surfaces of the membrane, as was the apical-to-basal flux of the drug. The apical peptide transporter had a significantly greater affinity for fosinopril than did the basolateral peptide transporter in Caco-2 cells (K(m), 154 versus 458 microM, respectively; p < 0.001) and SKPT cells (K(m), 22 versus 104 microM, respectively; p < 0.001). Moreover, fosinopril uptake by the basolateral peptide transporter was less sensitive to changes in medium pH than the apical peptide transporter in both cell lines. Although Caco-2 cells are known to express PEPT1 protein (and not PEPT2), our immunoblot analyses provide definitive evidence that SKPT cells express PEPT2 protein (and not PEPT1). Taken as a whole, our findings demonstrate that fosinopril is transported intact by PEPT2 and PEPT1, with high-affinity and by a proton-coupled, saturable process. Our results also suggest that distinct peptide transporters exist at the basolateral and apical membranes and that they play an important role in modulating the intestinal absorption and renal reabsorption of peptides and peptide-like drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560874

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

1.  Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes.

Authors:  Scott M Ocheltree; Richard F Keep; Hong Shen; Dongli Yang; Bret A Hughes; David E Smith
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

2.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors.

Authors:  Andrea S Heimann; Ivone Gomes; Camila S Dale; Rosana L Pagano; Achla Gupta; Laura L de Souza; Augusto D Luchessi; Leandro M Castro; Renata Giorgi; Vanessa Rioli; Emer S Ferro; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

Review 3.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 4.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

Review 5.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

6.  Ergovaline movement across Caco-2 cells.

Authors:  Nancy W Shappell; David J Smith
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Sep-Oct       Impact factor: 2.416

7.  Transport mechanisms of carnosine in SKPT cells: contribution of apical and basolateral membrane transporters.

Authors:  Dilara Jappar; Yongjun Hu; Richard F Keep; David E Smith
Journal:  Pharm Res       Date:  2008-09-27       Impact factor: 4.200

8.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

9.  Development of a QSAR model for binding of tripeptides and tripeptidomimetics to the human intestinal di-/tripeptide transporter hPEPT1.

Authors:  Rikke Andersen; Flemming Steen Jørgensen; Lars Olsen; Jon Våbenø; Karina Thorn; Carsten Uhd Nielsen; Bente Steffansen
Journal:  Pharm Res       Date:  2006-02-26       Impact factor: 4.200

Review 10.  Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications.

Authors:  David E Smith; Benjamin Clémençon; Matthias A Hediger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.